Pathology Clinical Faculty

Dr. Abi-Raad received her MD from Saint Joseph University- School of Medicine in Lebanon in 1994. She completed her residency in Anatomic and Clinical pathology and a fellowship in cytopathology at Yale New Haven Hospital. Dr. Abi-Raad is board certified in Clinical and Anatomic Pathology, and Cytopathology.

Dr. Adebowale Adeniran is an experienced surgical pathologist and cytopathologist, and currently Director of Cytopathology and the Cytology Laboratory. Dr. Adeniran obtained his MD degree from the University of Ibadan, Nigeria. He did his anatomic/clinical pathology residency at the University of Cincinnati Medical Center, followed by surgical pathology fellowship (with special interest in genitourinary pathology) at the University of Texas M.D. Anderson Cancer Center and cytopathology fellowship at the Memorial Sloan-Kettering Cancer Center. Dr. Adeniran is a practicing surgical and cyto pathologist, with a research focus on clinico-pathologic and molecular pathologic aspects of kidney cancer as well as thyroid cancer. He is a reviewer of several peer-reviewed journals including Thyroid, Acta Cytologica, Diagnostic Cytopathology and Cancer Cytopathology. He has authored more than 50 papers, 5 book chapters, and co-authored the textbook Common Diagnostic Pitfalls in Thyroid Cytopathology. He currently serves as Chairman, Publications and Newsletter committee of Papanicolaou Society of Cytopathology.

Andrea Barbieri is an associate professor in the Department of Pathology. She provides clinical care as a surgical pathologist with expertise in endocrine, head and neck, gastrointestinal and liver pathology. She is a Michigan native and received her undergraduate degree from Case Western Reserve University in Cleveland, Ohio and MD from Wayne State University School of Medicine in Detroit, Michigan. She subsequently completed her residency in Pathology and Laboratory Medicine at Yale New Haven Hospital in 2013 and gastrointestinal pathology fellowship at the Medical College of Wisconsin in 2014. She is board certified in anatomic and clinical pathology. She co-leads the Community and Visibility working group of the Dean's Advisory Council on LGBTQI+ Affairs. She serves as the Residency Program Director for the Anatomic and Clinical Pathology residency training program.

Marcus Bosenberg MD, PhD, is a physician scientist who directs a leading melanoma research laboratory, is Co-Leader of the Cancer Immunology Program of Yale Cancer Center, Director of the Yale Center for Immuno-Oncology, Contact PI of the Yale SPORE in Skin Cancer,  Director of the Center for Precision Cancer Modeling, and is a practicing dermatopathologist at Yale Dermatopathology through Yale Medicine.In his research, Dr. Bosenberg studies factors that regulate anti-cancer immune responses. His laboratory has developed several widely utilized mouse models in order to study how melanoma forms and progresses, to test new cancer therapies, and how the immune system can be stimulated to fight cancer. He works to translate basic scientific findings into improvements in cancer diagnosis and therapy. He has published over 200 peer-reviewed articles and is a member of the Yale Cancer Center Executive Committee.Dr. Bosenberg mentors undergraduate, graduate, medical, and MD-PhD students in his laboratory, teaches at Yale School of Medicine, and trains resident physicians, fellows, and postdoctoral fellows.

Demetrios Braddock was born in Tennessee, educated at the University of Chicago, trained at the NIH in Anatomic Pathology and Biophysical Chemistry, and came to Yale in 2004. He practices Hematopathology and a heads a laboratory whose focus is on rare diseases of children and the design and engineering of novel biologics to modulate disease outcome. Dr. Braddock's work on a rare disease of lethal vascular calcifications in infants called 'Generalized Arterial Calcification of Infancy' (GACI) led to the design and validation of an enzyme biologic which has successfully moved 'bench to bedside' into the clinic through the founding of Inozyme Pharma. Successful phase 1-2 clinical trial data in ENPP1 and ABCC6 deficiency was reported in Feb. 2023 (ClinicalTrials.gov: NCT04686175 & NCT05030831), and phase 3 studies are currently underway. Continued work on ENPP1 function includes the association of ENPP1 halploinsuffiency with early onset osteoporosis, the therapeutic effects of ENPP1 biologics on 'Paradoxical Mineralization' in prevalent medical diseases such as aging and chronic kidney disease, and the molecular mechanism by which an ENPP1 variant induces metabolic syndrome and obesity in children.

Dr. Buza completed her residency training in Anatomic Pathology, followed by a Fellowship in Gynecologic and Breast pathology at Yale University. She joined the faculty at Yale in 2010 where she is currently Professor of Pathology, Director of Pathology Center of Excellence for Women’s Health, and Director of the Gynecologic Pathology Fellowship Program. Dr. Buza authored/co-authored over 140 publications in the field of gynecologic pathology, including several review articles, book chapters, and a textbook dedicated to Intraoperative Frozen Section in Gynecologic Pathology. Most recently she contributed to multiple sections of the 5th edition of WHO Classification of Female Genital Tumours. Dr. Buza has been course faculty at the American Society for Clinical Pathology (ASCP) and United States and Canadian Academy of Pathology (USCAP) annual meetings, and at the USCAP Interactive Microscopy Center. Dr. Buza also served on the Abstract Review Board of USCAP, and she is an editorial board member of Modern Pathology, International Journal of Gynecological Pathology, and Human Pathology. Her main areas of academic interest include diagnostic, prognostic, and predictive markers of endometrial carcinoma, ovarian sex cord – stromal tumors, and gestational trophoblastic disease.

Dr. Cai completed his residency in Pathology and Laboratory Medicine at New York University Medical Center, where he also completed a fellowship in cytopathology. He is a board-certified pathologist and cytopathologist.

Dr. Chandler graduated from Yale School of Medicine and then completed her residency training in Pathology and Laboratory Medicine at Yale-New Haven Hospital. Subsequently, she completed two fellowships, one in cytopathology and the second in hematopathology, both at Yale.

Paul Cohen earned his MD at Columbia University in 1981. He completed his residency in anatomic pathology at Massachusetts General Hospital and the National Cancer Institute, where he also completed a pathology fellowship. Dr. Cohen is board certified in anatomic pathology. He is the Chair of Pathology at Bridgeport Hospital, and an Associate Professor of Pathology at Yale School of Medicine. Dr. Cohen is the Director of the Yale Pathology residency program at Bridgeport Hospital.

Dr. Colón-Cartagena completed her residency training in Anatomic and Clinical Pathology at Virginia Commonwealth University. She also completed Fellowship training in Oncologic and Breast Pathology at Memorial Sloan Kettering Cancer Center. She is interested in further understanding the behavior and histologic features of tumors of the breast.

Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology, assumed the position of Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine on May 1, 2022. She is also Professor of Pathology and Medical Director of the Tumor Profiling Lab (TPL) Dr. Dacic came to Yale from the University of Pittsburgh, where she was Professor of Pathology; Director of Anatomic Pathology at UPMC Presbyterian Hospital; Director of the Thoracic Pathology Center of Excellence; and Director of the FISH laboratory. She previously was Director of the Molecular Anatomic Pathology Laboratory at UPMC. Dr. Dacic received her medical and Doctor of Philosophy degrees at the School of Medicine, University of Zagreb, in Zagreb, Croatia, and completed her residency training at the University of Pittsburgh. Her research focuses on diagnostic pulmonary and molecular pathology and the development of prognostic biomarkers. She is a key leader of impactful basic and translational research projects in lung cancer and pleural mesotheliomas, which have resulted in hundreds of peer-reviewed scientific articles, practice guidelines, book chapters, and reviews. Dr. Dacic is a co-author of the original and revised College of American Pathologists/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology guidelines for molecular testing in lung cancer. In 2020, she was awarded the IASLC Award for Translational Research. She was a member of the Editorial Board for the 5th WHO Classification of Thoracic Tumors (2019). Dr. Dacic is a deputy editor in chief of Archives of Pathology & Laboratory Medicine and serves on the editorial boards of high impact journals. Dr. Dacic has served as a board member of the United States and Canadian Academy of Pathology (USCAP), as well as on its Education Committee and as a member and chair of its Young Investigators Awards Committee. She currently serves as president of the Pulmonary Pathology Society and is a member of the U.S. and Canadian Mesothelioma Group, the International Mesothelioma Panel, and the IASLC Pathology Committee.

I am a neuropathologist and researcher in neuroimmunology. My background is in electrophysiology and biomedical engineering of neural interface and neural information processing systems. My interests are in diseases of the central nervous system, including motor system diseases and cancer. I am working on advancing the techniques of computational pathology in order to better understand and diagnose diseases. My research involves the application of machine learning, image analysis, and statistics to histology and genomic data with the goal of better characterizing and classifying tumors. I am developing software to analyze histologic images taken from the kinds of slides produced in the routine clinical evaluation of tissue.  By using statistical and machine learning techniques, these algorithms look for patterns in cell placement and morphology that correspond to the tissue genetic profiles. I believe this simultaneous genotypic and phenotypic characterization of tumors will provide a deeper understanding of neurobiology, neuropathology, and caner immunology, and identify key elements of CNS microenvironments whose interactions advance our explanations and predictions of pathologic processes affecting the brain, retina, spinal cord, and peripheral nervous system.

Yale Medicine's Oral and Maxillofacial Pathology Program provides comprehensive diagnostic services on oral biopsy specimens. The service is led by Jeffrey Eskendri, DMD, a Board-Certified Oral and Maxillofacial Pathologist. He is a Diplomate in The American Board of Oral and Maxillofacial Pathology. Dr. Eskendri has also completed a Fellowship in Dental Oncology, in which he takes special interest. He holds an active Dental Licensure in Connecticut, New York, and Virginia. The service offers a multidisciplinary approach which includes a team of subspecialty pathologists from the Yale School of Medicine Department of Pathology. Our Oral and Maxillofacial Service is part of our Head, Neck, and Endocrine Program, a highly regarded high-volume service with subspecialty expertise, affording our clients the best personal service, turnaround times, and expert diagnoses.

Karin Finberg received her B.S., M.D., and Ph.D. degrees from Yale. Her Ph.D. dissertation with Dr. Richard Lifton in the Department of Genetics focused on the genetic basis of an autosomal recessive disorder of systemic pH homeostasis, distal renal tubular acidosis with sensorineural deafness. After graduating from Yale, Karin completed residency training in Clinical Pathology at Massachusetts General Hospital and clinical fellowship training in the Harvard Medical School Molecular Genetic Pathology Training Program based at Brigham and Women’s Hospital. She then completed postdoctoral research training in the laboratory of Dr. Nancy Andrews, first at Children’s Hospital Boston and later at Duke University Medical Center, where she employed genetic study of patients with an inherited form of iron deficiency anemia to shed insight into mechanisms of systemic iron regulation. In her research laboratory at Yale, Karin continues to investigate mechanisms of iron balance through genetic study of patients with iron-related phenotypes and through characterization of genetically targeted mouse models. She also contributes to patient care as a molecular genetic pathologist in the Molecular Diagnostics Unit of the Department of Pathology.

Anjela Galan, MD is Associate Professor of Dermatology and Pathology, and Director of Dermatopathology Fellowship and Training Program at Yale University School of Medicine. Dr. Galan specializes in dermatopathology (skin pathology) in the Department of Dermatology, as well as in Surgical Pathology at Yale New Haven Hospital, and at the Veterans Affairs Hospital in West Haven, Conn. In her work, she diagnoses tumors (neoplasms) and inflammatory skin disorders, using well-established and advanced techniques. After receiving her Medical Degree from “N. Testemitanu” Kishinev State Medical Institute (USSR), Dr. Galan completed a Pathology residency at Baystate Medical Center/Tufts University School of Medicine, followed by Oncologic Surgical Pathology and Dermatopathology Fellowships at Yale University School of Medicine. Dr. Galan is an integral member of Yale Cancer Center Melanoma Program, where she works closely with a specialized team that includes oncologic dermatologists, medical oncologists, oncologic surgeons, radiation oncologists, and basic science researchers, caring for patients with melanoma and a variety of other skin cancers. She is is a panel member of the National Comprehensive Cancer Network for melanoma. Dr. Galan's research interests include melanocytic and non-melanocytic neoplasms, infectious and granulomatous disorders. She enjoys practicing highly specialized dermatopathology, staying current with advancements in her field, and helping patients. Her guiding principle is simple: “Always do your best and treat every patient the way you would like to be treated.”

Dr. Gershkovich joined Pathology Department in 2004 shortly after completing the NLM funded fellowship training at Yale Center for Medical Informatics. Since that time, he led the development of novel, cutting-edge software to mesh emerging technologies with existing commercial Laboratory Information System, robotic laboratory instruments, Digital Pathology equipment, and the Hospital EMR.  Dr. Gershkovich is interested in clinical systems engineering, information visualization, DNA sequencing analysis, NLP, and full-text search of clinical data. He is currently focusing on how to better assemble, compile, and deliver relevant information at the point where a clinical decision needs to be made. The underlying philosophy in his software development is pragmatic reasoning which typically leads to the development of working systems that have meaningful impact on clinical care. The systems developed by his engineering group integrate into the daily workflow of the Pathology Department improving quality and efficiency of patient care and clinical operations.   At the onset of COVID epidemics, his group rapidly created and deployed a suite of software modules to support SARS-CoV-2 testing, further demonstrating that implanting software engineering activities in clinical services and translational research is essential for modern patient care. This work is critical for patient safety, the integration and accuracy of new diagnostic techniques, continuous quality improvement, and impactful workflow reengineering in medicine.

Dr. Gibson received her dual MD and PhD degrees at Mayo Medical School in Rochester, MN in 2004. She completed residency in anatomic and clinical pathology at Brigham and Women's Hospital in Boston, MA in 2008, where she also completed a fellowship in gastrointestinal and liver pathology in 2009. Dr. Gibson joined the Yale Pathology Faculty in August of 2011.

Dr. Glusac’s interests focus on the study of benign lesions that mimic malignant melanoma, a current topic of great interest in the field and the subject of many invited lectures, publications and editorials by Dr. Glusac. He has served the American Boards of Pathology and Dermatology and the editorial boards of the Journal of Cutaneous Pathology and the American Journal of Dermatopathology. He is past president of the American Society of Dermatopathology, and he is an author for the World Health Organization’s Classification of Tumours of the Skin.